8 recent FDA approvals

Eight drugs approved by the FDA since Oct. 18:

  1. Abrilada is Pfizer's biosimilar to AbbVie's blockbuster rheumatoid arthritis drug, Humira. The FDA's greenlight  brings the total number of approved biosimilars to 25.

  2. Adakveo, designated a breakthrough drug, is the first targeted therapy to treat sickle cell disease. It is made by Novartis.

  3. Fetroja is Shionogi & Co.'s antibiotic designed to treat complicated urinary tract infections. It is designed for patients age 18 or older who have limited or no alternative treatments.

  4. Brukinsa is BeiGeine USA's breakthrough lymphoma treatment. It is designed to treat adult patients with mantle cell lymphoma who have received at least one prior therapy.

  5. Reblozyl is Celegene's drug designed to treat anemia in adult patients with beta thalassemia who require regular red blood cell transfusions.

  6. Vumerity is Biogen and Alkermes' oral drug designed to treat relapsing forms of multiple sclerosis, a chronic disease that affects the central nervous system.

  7. Trikafta is Vertex Pharmaceuticals' breakthrough cystic fibrosis drug, designed to treat a mutation found in 90 percent of the U.S. cystic fibrosis population, or about  27,000 people.

  8. Xofluza is Genentech's flu treatment, the first approved antiviral drug designed specifically for patients with a high risk for serious flu complications.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars